W
WAVEMAN · COMPANY
BRVE · Braveheart Bio, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

BRVE

Braveheart Bio, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002131524
CLUSTER · 10 INSIDERSACTIVIST 13DC-SUITE BUYING · 3☆ WATCH
INSIDER NET · 180D
$119.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
10
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
6
codes C/M, not in net · $0 priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$119.0M over 180 days
+$119.0M over 90 days · +$114.4M of it by a 10%+ holder
the highest in Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
10 insiders independently bought a net $119.0M — no planned sales are queued against it.
ORBIMED ADVISORS LLC disclosed a 5%+ stake (17.2%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -10.3%
-10.3%12M
-16%-10%-5%+1%2026-082026-082026-082026-082026-082026-082026-092026-09 2026-08-07 · Forbion Growth Opportunities Fund III Cooperatief U.A. bought $34.6M2026-08-07 · ORBIMED ADVISORS LLC bought $30.0M2026-08-07 · Chimovits Erez bought $30.0M2026-08-07 · AH Bio Fund IV, L.P. bought $19.8M2026-08-07 · Viehbacher Christopher bought $1.5M2026-08-07 · Murdoch Travis bought $1.5M2026-08-07 · Lubner David Charles bought $1,000.0K2026-08-07 · Rickey James Paul bought $500.0K2026-08-07 · Malek David I bought $75.0K2026-08-07 · Anderson Michele A. bought $20.0K2026-08-18 · ORBIMED ADVISORS LLC filed a 5%+ stake (17.2%)2026-08-18 · OrbiMed Capital GP IX LLC filed a 5%+ stake (16.9%)2026-08-18 · OrbiMed Genesis GP LLC filed a 5%+ stake (0.4%)2026-08-14 · AH Bio Fund IV, L.P. filed a 5%+ stake (11.4%)2026-08-14 · AH Equity Partners Bio IV, L.L.C. filed a 5%+ stake (11.4%)2026-08-14 · Marc L. Andreessen filed a 5%+ stake (11.4%)2026-08-14 · Benjamin A. Horowitz filed a 5%+ stake (11.4%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
10 insiders reported buying shares.
The record shows a net $119.0M bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Braveheart Bio, Inc. insiders bought a net $119.0M of stock across 10 Form 4 purchases and sales, with 10 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Viehbacher Christopher
Director
BUY
2026-08-07
83,333.0
$1.5M
Malek David I
Director
BUY
2026-08-07
4,166.0
$75.0K
Anderson Michele A.
Chief Development Officer
BUY
2026-08-07
1,111.0
$20.0K
Murdoch Travis
CEO and President
BUY
2026-08-07
83,333.0
$1.5M
Lubner David Charles
Director
BUY
2026-08-07
55,555.0
$1,000.0K
10 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 5 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

5%+ owners
13D = intent to influence · 13G = passive
ORBIMED ADVISORS LLC
ACTIVIST 13D · 2026-08-18
17.2%
OrbiMed Capital GP IX LLC
ACTIVIST 13D · 2026-08-18
16.9%
OrbiMed Genesis GP LLC
ACTIVIST 13D · 2026-08-18
0.4%
AH Bio Fund IV, L.P.
ACTIVIST 13D · 2026-08-14
11.4%
AH Equity Partners Bio IV, L.L.C.
ACTIVIST 13D · 2026-08-14
11.4%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 3
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →